IL6Hemmer
IL6Hemmer, or IL-6 inhibitors, are a class of medications that block interleukin-6 (IL-6) signaling. They include monoclonal antibodies that neutralize IL-6 itself or target the IL-6 receptor (IL-6R). By interrupting the IL-6 pathway, these drugs reduce inflammation and the acute-phase response, which can be observed as lower levels of inflammatory markers such as C-reactive protein.
Two main approaches exist: antibodies against IL-6 (for example, siltuximab) and antibodies against the IL-6 receptor
Administration is typically via subcutaneous injection or intravenous infusion, with dosing tailored to the specific indication.
Development and impact: IL-6 pathway blockade has become an important strategy in targeted immunotherapy for inflammatory